LD-2 disclosure · 4th Quarter - Report
REGENERON PHARMACEUTICALS, INC
Client
- Location
- New York · United States of America
Registrant
- Description
- Biopharmaceutical development and manufacturing
- Location
- TARRYTOWN, New York, United States of America
Lobbying activities
3 issuesHealth Issues
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
LobbyistsMAYA BERMINGHAM · VALERIE VOLPE · KATHERINE HADDAD · MADDIE DAVIDSON · EBEN DUROSS
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers, including ancillary care and prior authorization
LobbyistsVALERIE VOLPE · KATHERINE HADDAD · MADDIE DAVIDSON · EBEN DUROSS
TargetedSENATE · HOUSE OF REPRESENTATIVES
Copyright/Patent/Trademark
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
VALERIE VOLPE